




Suppl Figure S1: Expression, regulation and functions of α Syn in the DRGs




Suppl. Figure S1: Expression, regulation and functions of α Syn in the DRGs. (A) immunofluorescence showing α Syn (red), CGRP (blue), IB4 (green) and merge, (B) immunofluorescence showing α Syn (red), CGRP (blue), NF200 (green) and merge in the DRG of wild type mice, (C) Protein regulation of α Syn in the DRG after formalin injection into the paw (n = 4-10), (D) Protein regulation of α Syn in the DRG in sham and SNI-treated mice (n = 4-8), (E) Regulation of CB1R mRNA in the DRG of Wild type and Snca knock-out mice after sham and SNI treatment (n=3).



Suppl. Figure S2: Zymosan-induced paw inflammation. Dynamic plantar test to assess mechanical allodynia in the paw after injection of zymosan A in wild type and Snca knock-out mice. The diagram shows the delta paw withdrawal latency (Δ PWL) which was calculated as the percentage ratio between the ipsi- and contralateral paw. n = 7-8.




Suppl. Figure S3: Mechanical and cold allodynia in the SNI model, (A) Paw withdrawal latencies of ipsi- and contralateral paws in the SNI. Dynamic plantar test to assess mechanical allodynia in wild type and Snca knock-out mice after SNI. n = 12 WT/13KO. (B) Cold allodynia as assessed in the acetone test after SNI surgery. The left diagram shows the time course after SNI, the right diagram the total reaction time per group (n =3).



Suppl. Figure S4: Expression of delta-opioid receptor (DOR) and cannabinoid receptor 1 (CB1 R) genes in the spinal cord of mice in the SNI model. Relative mRNA expression of DOR and CB1 R in the spinal cord of wild type and SNCA knock-out mice after sham or 7 and 14d after SNI surgery, respectively. For better comparison, the wild type sham control has been set as 1. * $p < 0.05$, *** $p < 0.001$ statistically significant difference between the genotypes, # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ statistically significant difference between Sham and SNI.

Suppl Figure S5: Immunofluorescence background



Suppl. Figure S5: Immunofluorescence background control staining, immunofluorescence was performed with the same conditions as described but without primary antibodies. Left: Cy-3 background, middle: AlexaFluor-488 staining, right: merge, Scale bars = 50 μm